Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

Por Strand, Vibeke, Kosinski, Mark, Gnanasakthy, Ari, Mallya, Usha, Mpofu, Shephard
Publicado em 2014

Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines

Por Mauskopf, Josephine, Samuel, Miny, McBride, Doreen, Mallya, Usha G., Feldman, Steven R.
Publicado em 2014

Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease

Por Mallya, Usha G., Boklage, Susan H., Koren, Andrew, Delea, Thomas E., Mullins, C. Daniel
Publicado no Pharmacoeconomics (2017)

Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA

Por Chu, David S, Johnson, Scott J, Mallya, Usha G, Davis, Matthew R, Sorg, Rachael A, Duh, Mei Sheng
Publicado em 2013

Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©

Por Jacobson, Terry A., Edelman, Steven V., Galipeau, Nina, Shields, Alan L., Mallya, Usha G., Koren, Andrew, Davidson, Michael H.
Publicado no Patient (2016)